REAL-WORLD OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND SUBSTANCE ABUSE DISORDERS TREATED WITH GLECAPREVIR/PIBRENTASVIR FOR 8 WEEKS: A POOLED ANALYSIS OF MULTINATIONAL POST-MARKETING OBSERVATIONAL STUDIES

被引：0

作者：

Rizzardini, Giuliano ^{[1
]}

Gschwantler, Michael ^{[2
]}

Bourgeois, Stefan ^{[3
]}

Mullhaupt, Beat ^{[4
,5
]}

Mazur, Wlodzimierz ^{[6
]}

Bondin, Mark ^{[7
]}

Zhang, Zhenzhen ^{[7
]}

Marra, Fiona ^{[8
]}

Veitsman, Ella ^{[9
]}

Mimidis, Konstantinos ^{[10
]}

Marques, Nuno ^{[11
]}

Foucher, Juliette ^{[12
]}

机构：

[1] Asst Fatebenefratelli Sacco, Div Infect Dis 1, Milan, Italy

[2] Wilhelminenspital Stadt Wien, Dept Internal Med 4, Vienna, Austria

[3] Stuivenberg Zna, Antwerp, Belgium

[4] Univ Hosp Zurich, Dept Gastroenterol & Hepatol, Zurich, Switzerland

[5] Univ Zurich, Zurich, Switzerland

[6] Med Univ Silesia, Clin Dept Infect Dis, Katowice, Poland

[7] Abbvie Inc, N Chicago, IL USA

[8] Univ Liverpool, Hepatol Drug Interact Grp, Liverpool, Merseyside, England

[9] Rambam Hlth Care Campus, Liver Unit, Haifa, Israel

[10] Democritus Univ Thrace, Sch Med, Dept Internal Med 1, Xanthi, Greece

[11] Hosp Garcia Orta Epe, Infect Dis Serv, Almada, Portugal

[12] Hop Haut Leveque, Pessac, France

来源：

HEPATOLOGY | 2020年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

929

引用

页码：568A / 569A

页数：2

共 47 条

[41] Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Liu, Chen-Hua
Peng, Cheng-Yuan
Liu, Chun-Jen
Chen, Chi-Yi
Lo, Ching-Chu
Tseng, Kuo-Chih
Su, Pei-Yuan
Kao, Wei-Yu
Tsai, Ming-Chang
Tung, Hung-Da
Cheng, Hao-Tsai
Lee, Fu-Jen
Huang, Chia-Sheng
Huang, Ke-Jhang
Shih, Yu-Lueng
Yang, Sheng-Shun
Wu, Jo-Hsuan
Lai, Hsueh-Chou
Fang, Yu-Jen
Chen, Po-Yueh
Hwang, Jow-Jyh
Tseng, Chi-Wei
Su, Wei-Wen
Chang, Chun-Chao
Lee, Pei-Lun
Chen, Jyh-Jou
Chang, Chi-Yang
Hsieh, Tsai-Yuan
Chang, Chung-Hsin
Huang, Yi-Jie
Kao, Jia-Horng
HEPATOLOGY INTERNATIONAL, 2023, 17 (02) : 291 - 302
[42] Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Chen-Hua Liu
Cheng-Yuan Peng
Chun-Jen Liu
Chi-Yi Chen
Ching-Chu Lo
Kuo-Chih Tseng
Pei-Yuan Su
Wei-Yu Kao
Ming-Chang Tsai
Hung-Da Tung
Hao-Tsai Cheng
Fu-Jen Lee
Chia-Sheng Huang
Ke-Jhang Huang
Yu-Lueng Shih
Sheng-Shun Yang
Jo-Hsuan Wu
Hsueh-Chou Lai
Yu-Jen Fang
Po-Yueh Chen
Jow-Jyh Hwang
Chi-Wei Tseng
Wei-Wen Su
Chun-Chao Chang
Pei-Lun Lee
Jyh-Jou Chen
Chi-Yang Chang
Tsai‐Yuan Hsieh
Chung-Hsin Chang
Yi-Jie Huang
Jia-Horng Kao
Hepatology International, 2023, 17 : 291 - 302
[43] SEVERE IMPAIRMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY
Younossi, Zobair M.
Yu, Ming-Lung
El Kassas, Mohamed
Esmat, Gamal
Yilmaz, Yusuf
Fernandez, Marlen Castellanos
Duseja, Ajay K.
Isakov, Vasily A.
Buti, Maria
Mendez-Sanchez, Nahum
Papatheodoridis, George V.
Chan, Wah Kheong
George, Jacob
Bugianesi, Elisabetta
Romero-Gomez, Manuel
Roberts, Stuart K.
Younes, Ziad
Wong, Vincent Wai-Sun
Fan, Jian-Gao
Eguchi, Yuichiro
Gordon, Stuart C.
Ahmed, Aijaz
Ong, Janus
Jacobson, Ira M.
Arrese, Marco
Rinella, Mary E.
Hamid, Saeed S.
Younossi, Issah
Lam, Brian P.
Ziayee, Mariam
Nader, Fatema
Racila, Andrei
Henry, Linda
Stepanova, Maria
HEPATOLOGY, 2019, 70 : 359A - 360A
[44] Regional and Practice Setting Differences in Real-World Treatment Rates of Chronic Hepatitis C (CHC) Infection Worldwide: A Meta-Analysis of 21 Studies and 324,496 Patients
Vutien, Philip
Jin, Michelle
Le, MIchael H.
Nguyen, Pauline
Trinh, Sam
Chuang, Wan-Long
Yu, Ming-Lung
Nguyen, Mindie H.
GASTROENTEROLOGY, 2016, 150 (04) : S1061 - S1062
[45] High rates of sustained virological response at 12 weeks in a real-world hospital-based cohort of direct-acting antiviral-treated patients with hepatitis C virus (HCV): The Observational, Prospective Epidemiological Registry in Australia of HCV (OPERA-C)
Clark, P.
Valery, P.
Strasser, S.
Leggett, B.
Levy, M.
Zekry, A.
Rong, J.
Sinclair, M.
George, J.
Tse, E.
Mcgarity, B.
Weltman, M.
Macquillan, G.
Bollipo, S.
Sievert, W.
Thompson, A.
Roberts, S.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 79 - 79
[46] SUSTAINED VIROLOGIC RESPONSE (SVR) IN AMERICAN NAIVE MONO-INFECTED CHRONIC HEPATITIS C (CHC) PATIENTS (PTS) TREATED WITH PEGINTERFERON ALFA (PEGIFNα) PLUS RIBAVIRIN (RBV): FINAL ANALYSIS OF THE LARGE, MULTINATIONAL REAL-WORLD PROPHESYS DATABASE
Nelson, David R.
Hassanein, Tarek
Shiffman, Mitchell L.
Rodriguez-Torres, Maribel
Pruthi, Jatinder
Tice, Alan D.
Herring, Robert W.
Beavers, Kimberly L.
Schmitz, Manuela
Hamzeh, Fayez
HEPATOLOGY, 2011, 54 : 865A - 866A
[47] IMPACT OF AGE >65 YEARS ON SVR AND RELAPSE IN CHRONIC HEPATITIS C (CHC) PATIENTS (PTS) TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGIFNα2A[40KD]) PLUS RIBAVIRIN (RBV): FINAL ANALYSIS FROM THE LARGE MULTINATIONAL REAL-WORLD PROPHESYS COHORTS
Aronsohn, Andrew
Ancuta, Ioan
Caruntu, Florin A.
Coppola, Carmine
Delic, Dragan
Digiacomo, Antonio
Dusheiko, Geoffrey M.
Lengyel, Gabriella
Marcellin, Patrick
Orlandini, Alessandra
Pruthi, Jatinder
Silva, Giovanni Faria
Tallarico, Ludovico G.
Schmitz, Manuela
Hamzeh, Fayez
Cheinquer, Hugo
HEPATOLOGY, 2011, 54 : 836A - 836A

← 1 2 3 4 5 →